Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $18.00 target price on the stock. D. Boral Capital’s price target suggests a potential upside of 165.10% from the company’s current price.

Separately, Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, February 6th.

Coya Therapeutics Trading Down 0.9 %

Shares of COYA opened at $6.79 on Tuesday. The stock has a 50 day moving average of $6.29 and a 200 day moving average of $6.48. The company has a market capitalization of $113.44 million, a price-to-earnings ratio of -10.45 and a beta of 0.31. Coya Therapeutics has a 12 month low of $4.75 and a 12 month high of $10.69.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC lifted its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in shares of Coya Therapeutics during the 4th quarter valued at about $401,000. CM Management LLC boosted its stake in Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after buying an additional 15,941 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Coya Therapeutics during the 4th quarter valued at $74,000. Finally, Northern Trust Corp lifted its stake in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.